Loading…
← CockpitCompetitor Analysis › 377740.KS BioNote, Inc.Open in the cockpit ↗

BioNote, Inc.377740.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Medical Specialties
Momentum strong 75
Mkt cap
$337M
US dollars, full cap
Free float
13%
of shares outstanding
$/day
$231,551
20-day average traded
Fwd P/E
14.4×
forward earnings
ROIC−WACC
-4.0 pp
WACC 5.6%
Hurdle
+13 pp
Req g minus delivered
Next earnings
104 days
2 Mar 2027
Close · KRW₩4,450
1D-0.9%
1W-2.3%
1M-2.4%
3M-9.7%
6M-13.6%
YTD-18.6%
1Y-19.5%
ATR %3.4%
52w lowhigh28.9% off high

What BioNote does

Employees: 334

BioNote at a glance

Size BioNote (377740.KS) is a South Korea Health Care company (Medical Specialties) with a market value of $337M, the 449th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩4,450 on 18 Nov 2026.

Performance Over six months the shares fell 13.6%, against -16.7% for the median peer and -37.2% for the South Korea market (cap-weighted) — 10th highest of 21 in its peer set.

Growth Revenue grew 12.1% over the last twelve months (peer median +2.2%); the operating margin is 18.4% (peer median 7.9%).

Valuation It trades at 14.4× forward earnings against a peer median of 17.8× (4th cheapest of 13).

Price implies For today's price to make sense, revenue must grow about -15% a year for seven years (Req g). Recent delivered growth is -28%, so the hurdle is +13 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 4.0 points below its cost of capital (5.6% WACC).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010021 May 202621 Aug 202618 Nov 2026377740.KS 89Peer median 84
Six months, rebased to 100: BioNote against the median of its 20 peers (local-currency closes).

BioNote financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩129B₩118B₩103B₩90.1B₩480B
Revenue growth—+15%+14%-81%—
Gross profit₩70.0B₩63.0B₩49.3B-₩13.4B₩340B
EBITDA₩33.9B₩26.0B₩20.0B-₩39.0B₩302B
Net income-₩209B-₩87.5B₩55.3B-₩20.5B₩308B
Free cash flow₩27.6B₩6.27B₩47.5B-₩8.16B₩207B
Capital expenditure₩20.6B₩8.27B₩10.5B₩4.54B₩42.5B
Total debt₩4.15B₩3.65B₩3.93B₩4.93B₩1.36B

Quarterly statements and history in the cockpit →

BioNote competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%-10%0%688273301502CLTNYDESEMBC197A688468300753300942VBSN58896883381609SBSCVBWAY3005626885766748377740.KS6-month return →1-month return →
Up and to the right = strong over both horizons. BioNote is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%0×250×500×750×688273CLTNEMBC197A3007535889BWAY300562688576377740.KSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. BioNote is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-20%0%20%40%688273301502CLTNEMBC688468300753VBSN30065358896883381609BWAY300562377740.KSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. BioNote is the large dot.

BioNote competitors and peer comparison

How BioNote compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

BioNote against its 20 peers (data as of 18 Nov 2026)
Measure377740.KSPeer medianRank in peer set
1-month return-2.4%-10.9%6th highest of 21
6-month return-13.6%-16.7%10th highest of 21
Distance from 52-week high-28.9%-45.3%6th highest of 21
Revenue growth (TTM)+12.1%+2.2%7th highest of 21
Operating margin18.4%7.9%6th highest of 21
Forward P/E14.4×17.8×4th cheapest of 13
Growth the price implies (Req g, 7 yrs)-15.0%10.7%2nd least demanding of 15
Growth delivered (Del g)-28.5%+0.2%lowest of 15
Hurdle (Req g minus delivered)+13.4 pp+4.2 pp7th most demanding of 15
ROIC minus cost of capital-4.0 pp+5.4 pp8th lowest of 19
EV / EBITDA3.8×8.9×cheapest of 10
Net debt / EBITDA-9.4×1.3×2nd least indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
BioNote 377740.KSSouth Korea$337M-14%+12%18%14.4×-15.0%-28.5%
Nanjing Medlander Medical Technology 688273.SSChina$337M-47%-12%8%17.5×35.3%+5.2%
Jiangsu Huayang Intelligent Equipment 301502.SZChina$336M-36%-5%2%n/a34.3%+0.4%
COLTENE CLTN.SWSwitzerland$339M-7%-2%8%25.2×-0.3%-0.7%
YD Bio YDESUnited States$344M+7%+17%-883%n/an/an/a
Embecta EMBCUnited States$345M+99%-8%26%3.8×-19.9%-0.1%
Tauns Laboratories 197A.TJapan$327M-3%+7%29%16.7×n/an/a
Chemclin Diagnostics 688468.SSChina$327M-24%-10%4%n/a15.8%-4.5%
Jiangsu Apon Medical Technology 300753.SZChina$326M-34%-15%-10%862.0×20.0%-5.1%
Shenzhen Bioeasy Biotechnology 300942.SZChina$326M-27%+12%-2%n/an/an/a
IVF HARTMANN VBSN.SWSwitzerland$352M-2%+7%14%n/a-12.7%-1.3%
Yantai Zhenghai Bio-Tech 300653.SZChina$354M-23%-8%17%36.0×18.4%+4.4%
Japan Eyewear 5889.TJapan$318M-5%+15%32%10.7×-9.4%+20.2%
Beijing Succeeder Technology 688338.SSChina$362M-18%-4%31%16.4×5.7%+3.4%
Star Sports Medicine 1609.HKHong Kong$364M-73%+23%37%n/a-13.1%+36.8%
Stratec SBS.DEGermany$365M+63%-6%4%18.2×19.1%+0.1%
CapsoVision CVUnited States$366M+5%+15%-213%n/an/an/a
Brainsway Ltd Sponsored ADR BWAYUnited States$373M-41%+32%14%20.3×24.9%+18.8%
Guangdong Transtek Medical Electronics 300562.SZChina$373M-15%+7%11%25.3×-4.2%-6.0%
Chongqing Xishan Science and Technology 688576.SSChina$301M-40%-23%-29%12.8×n/an/a
ACRO Biomedical 6748.TWOTaiwan$377M+158%+45%-178%n/an/an/a

Questions

Which companies are BioNote's closest peers?
The cockpit's peer set: Nanjing Medlander Medical Technology (688273.SS), Jiangsu Huayang Intelligent Equipment (301502.SZ), COLTENE (CLTN.SW), YD Bio (YDES), Embecta (EMBC), Tauns Laboratories (197A.T), Chemclin Diagnostics (688468.SS), Jiangsu Apon Medical Technology (300753.SZ).
Is BioNote expensive compared with its peers?
On forward p/e it trades at 14.4× against a peer median of 17.8×, 4th cheapest of 13 in its peer set. For today's price to make sense, revenue must grow about -15% a year for seven years (Req g). Recent delivered growth is -28%, so the hurdle is +13 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has BioNote stock performed?
Over six months to 18 Nov 2026 the shares returned -13.6% against -16.7% for the median peer; over one year -19.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.